Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2362-2368

  Iriyama, Noriyoshi ^a   Yuan, Bo ^b   Yoshino, Yuta ^b   Hatta, Yoshihiro ^a   Horikoshi, Akira ^a   Aizawa, Shin ^a   Takeuchi, Jin ^a   Toyoda, Hiroo ^b  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Acute promyelocytic leukemia; Aquaporin 9; Arsenic trioxide; HT93A; NB4

Indexed keywords

AQUAPORIN 9; ARSENIC TRIOXIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG UPTAKE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN ANALYSIS; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; AQUAPORINS; ARSENICALS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GENE EXPRESSION; HL-60 CELLS; HUMANS; JURKAT CELLS; K562 CELLS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES;

EID: 84876237223     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2388     Document Type: Article

References (37)

1. de Thé H, Chomienne C, Lanotte M, Degos L and Dejean A: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347: 558-561, 1990.
2. Goddard AD, Borrow J, Freemont PS and Solomon E: Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 254: 1371-1374, 1991. (Pubitemid 21917471)
3. Tong JH, Dong S, Geng JP, Huang W, Wang ZY, Sun GL, Chen SJ, Chen Z, Larsen CJ and Berger R: Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a breakpoint cluster region as well as some molecular variants. Oncogene 7: 311-316, 1992.
4. Burnett AK, Grimwade D, Solomon E, Wheatley K and Goldstone AH: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all- trans retinoic acid: result of the Randomized MRC Trial. Blood 93: 4131-4143, 1999. (Pubitemid 29279255)
5. Melnick A and Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93: 3167-3215, 1999. (Pubitemid 29220886)
6. Cohen MH, Hirschfeld S, Flamm Honig S, Ibrahim A, Johnson JR, O'Leary JJ, White RM, Williams GA and Pazdur R: Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 6: 4-11, 2001. (Pubitemid 32155810)
7. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360, 1997.
8. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP and Warrell RP Jr: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348, 1998. (Pubitemid 28509343)
9. Dilda PJ and Hogg PJ: Arsenical-based cancer drugs. Cancer Treat Rev 33: 542-564, 2007. (Pubitemid 47355338)
10. Litzow MR: Arsenic trioxide. Expert Opin Pharmacother 9: 1773-1785, 2008.
11. Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y, Hashimoto H, Kinoshita K, Shimoya M, Kaise T and Ohnishi K: Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother Pharmacol 59: 485-493, 2007. (Pubitemid 46122327)
12. Iriyama N, Yoshino Y, Yuan B, Horikoshi A, Hirabayashi Y, Hatta Y, Toyoda H and Takeuchi J: Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. J Hematol Oncol 5: 1-11, 2012.
13. Kiguchi T, Yoshino Y, Yuan B, Yoshizawa S, Kitahara T, Akahane D, Gotoh M, Kaise T, Toyoda H and Ohyashiki K: Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res 34: 403-405, 2010.
14. Yoshino Y, Yuan B, Miyashita SI, Iriyama N, Horikoshi A, Shikino O, Toyoda H and Kaise T: Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem 393: 689-697, 2009. (Pubitemid 50331982)
15. Yuan B, Yoshino Y, Kaise T and Toyoda H: Application of arsenic trioxide therapy for patients with leukaemia. In: Biological Chemistry of As, Sb and Bi. Sun HZ (ed). John Wiley and Sons, Ltd., New York, pp263-292, 2011.
16. Bhattacharjee H, Carbrey J, Rosen BP and Mukhopadhyay R: Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem Biophys Res Commun 322: 836-841, 2004. (Pubitemid 39164428)
17. Lee TC, Ho IC, Lu WJ and Huang JD: Enhanced expression of multidrug resistance-associated protein 2 and reduced expression of aquaglyceroporin 3 in an arsenic-resistant human cell line. J Biol Chem 281: 18401-18407, 2006.
18. Leung J, Pang A, Yuen WH, Kwong YL and Tse EW: Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood 109: 740-746, 2007. (Pubitemid 46105976)
19. Liu Z, Shen J, Carbrey JM, Mukhopadhyay R, Agre P and Rosen BP: Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci USA 99: 6053-6058, 2002. (Pubitemid 34493263)
20. Yoshino Y, Yuan B, Kaise T, Takeichi M, Tanaka S, Hirano T, Kroetz DL and Toyoda H: Contribution of aquaporin 9 and multidrug resistance-associated protein 2 to differential sensi tivity to arsenite between primary cultured chorion and amnion cells prepared from human fetal membranes. Toxicol Appl Pharmacol 257: 198-208, 2011.
21. Hu J, Liu YF, Wu CF, Xu F, Shen ZX, Zhu YM, Li JM, Tang W, Zhao WL, Wu W, Sun HP, Chen QS, Chen B, Zhou GB, Zelent A, Waxman S, Wang ZY, Chen SJ and Chen Z: Long-term efficacy and safety of all- trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 106: 3342-3347, 2009.
22. Yuan B, Ohyama K, Bessho T and Toyoda H: Contribution of inducible nitric oxide synthase and cyclooxygenase-2 to apoptosis induction in smooth chorion trophoblast cells of human fetal membrane tissues. Biochem Biophys Res Commun 341: 822-827, 2006. (Pubitemid 43177564)
23. Yuan B, Ohyama K, Bessho T, Uchide N and Toyoda H: Imbalance between ROS production and elimination results in apoptosis induction in primary smooth chorion trophoblast cells prepared from human fetal membrane tissues. Life Sci 82: 623-630, 2008.
24. Yuan B, Ohyama K, Takeichi M and Toyoda H: Direct contri bution of inducible nitric oxide synthase expression to apoptosis induction in primary smooth chorion trophoblast cells of human fetal membrane tissues. Int J Biochem Cell Biol 41: 1062-1069, 2009.
25. Wang ZY and Chen Z: Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515, 2008.
26. 3 exerts dose-dependent dual effects on APL cells. Blood 89: 3345-3353, 1997.
27. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ and Chen Z: Arsenic trioxide, a therapeutic agent for APL. Oncogene 20: 7146-7153, 2001.
28. Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D and Rodeghiero F: Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 87: 250-256, 2002. (Pubitemid 34212440)
29. Ferrara F, Morabito F, Martino B, Specchia G, Liso V, Nobile F, Boccuni P, Di Noto R, Pane F, Annunziata M, Schiavone EM, De Simone M, Guglielmi C, Del Vecchio L and Lo Coco F: CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all- trans -retinoic acid and chemotherapy. J Clin Oncol 18: 1295-1300, 2000. (Pubitemid 30159848)
30. Montesinos P, Rayon C, Vellenga E, Brunet S, Gonzalez J, Gonzalez M, Holowiecka A, Esteve J, Bergua J, Gonzalez JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Perez I, Perez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B and Sanz MA: Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 117: 1799-1805, 2011.
31. Schwarzinger I, Valent P, Koller U, Marosi C, Schneider B, Haas O, Knapp W, Lechner K and Bettelheim P: Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 8: 423-430, 1990. (Pubitemid 20087543)
32. Vahdat L, Maslak P, Miller WH Jr, Eardley A, Heller G, Scheinberg DA and Warrell RP Jr: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84: 3843-3849, 1994.
33. Andus T, Targan SR, Deem R and Toyoda H: Measurement of tumor necrosis factor alpha mRNA in small numbers of cells by quantitative polymerase chain reaction. Reg Immunol 5: 11-17, 1993. (Pubitemid 23189150)
34. Ruan XZ, Varghese Z, Powis SH and Moorhead JF: Human mesangial cells express inducible macrophage scavenger receptor. Kidney Int 56: 440-451, 1999. (Pubitemid 29353141)
35. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z and Chen GQ: Arsenic trioxide-induced apoptosis and differentiation are asso ciated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 14: 262-270, 2000. (Pubitemid 30095381)
36. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88: 1052-1061, 1996.
37. Iriyama N, Yuan B, Hatta Y, Horikoshi A, Yoshino Y, Toyoda H, Aizawa S and Takeuchi J: Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A. Oncol Rep 28: 1875-1882, 2012.